

# Product Datasheet

## EIF3C Antibody - BSA Free

### NB100-511

Unit Size: 100 ul

Store at 4C. Do not freeze.

[www.novusbio.com](http://www.novusbio.com)



[technical@novusbio.com](mailto:technical@novusbio.com)

**Reviews: 1** **Publications: 5**

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:  
[www.novusbio.com/NB100-511](http://www.novusbio.com/NB100-511)

Updated 9/9/2025 v.20.1

Earn rewards for product  
reviews and publications.

Submit a publication at [www.novusbio.com/publications](http://www.novusbio.com/publications)

Submit a review at [www.novusbio.com/reviews/destination/NB100-511](http://www.novusbio.com/reviews/destination/NB100-511)



**NB100-511**

EIF3C Antibody - BSA Free


Product Information	
Unit Size	100 ul
Concentration	1.0 mg/ml
Storage	Store at 4C. Do not freeze.
Clonality	Polyclonal
Preservative	0.09% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	Tris-Citrate/Phosphate (pH 7.0 - 8.0)
Target Molecular Weight	105 kDa

Product Description	
Description	Novus Biologicals Rabbit EIF3C Antibody - BSA Free (NB100-511) is a polyclonal antibody validated for use in WB and IP. Anti-EIF3C Antibody: Cited in 5 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	8663
Gene Symbol	EIF3C
Species	Human, Mouse
Reactivity Notes	Mouse reactivity reported in (PMID: 28241004).
Immunogen	A synthetic peptide derived from a sequence between residues 850 and 918 (the C-terminus) of human eukaryotic translation initiation factor 3, subunit 8, 110kDa using the numbering given in Swiss-Prot entry Q99613 (GeneID 8663).


Product Application Details	
Applications	Western Blot, Immunoprecipitation
Recommended Dilutions	Western Blot 1:2000 - 1:10000, Immunoprecipitation 2-10 ug/mg lysate
Application Notes	EIF3C antibody validated for WB from a verified customer review.

**Images**


Western Blot: EIF3C Antibody [NB100-511] - eIF3C expression in naive and activated (overnight) murine B cells. Image submitted by a verified customer review.




Western Blot: EIF3C Antibody [NB100-511] - Detection of Human eIF3C/eIF3S8 by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, and Jurkat cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-eIF3C/eIF3S8 antibody NB100-511 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.




Immunoprecipitation: EIF3C Antibody [NB100-511] - Detection of human eIF3C/eIF3S8 by western blot of immunoprecipitates. Samples: Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-eIF3C/eIF3S8 antibody NB100-511 used for IP at 6 ug per reaction. eIF3C/eIF3S8 was inefficiently immunoprecipitated by rabbit anti-eIF3C/eIF3S8 antibody from Company B. For blotting immunoprecipitated eIF3C/eIF3S8, NB100-511 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.



EIF3C is a potential target for CFH to play a role in inhibiting FLSs and monocyte function. Monocytes and FLS from RA patients were selected respectively, and cells from each patient were divided into two groups. One group was left untreated, and one group was treated with 5  $\mu$ g/ml CFH for 6 h. A Volcano plot indicated up-regulated (red dots) and down-regulated (blue dots) genes ( $P$  value  $< 0.05$  and  $|\log_2FC| > 0.5$ ) by RNA sequencing in CFH-treated versus untreated RA monocytes. EIF3C is indicated. B Volcano plot indicated up-regulated (red dots) and down-regulated (blue dots) genes ( $P$  value  $< 0.05$  and  $|\log_2FC| > 0.5$ ) by RNA sequencing in CFH-treated versus untreated RA monocytes. EIF3C and EIF3CL are indicated. C We selected the genes upregulated in the CFH-treated monocytes and the genes upregulated in the CFH-treated FLS identified by RNA-sequencing and determined the intersecting proteins. We obtained one gene, namely EIF3C. DEGs: Differentially Expressed Genes. D The boxplot shows the relative expression of EIF3C and EIF3CL. E CFH upregulated the protein expression of EIF3C by using Western blot. F CFH combined with TNF- $\alpha$  upregulated protein expression of EIF3C in both RA FLSs and monocytes by using Western blot. Data are expressed as mean  $\pm$  SEM ( $n = 6$ ). \* $p < 0.05$  Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/37996918>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



EIF3C is a potential target for CFH to play a role in inhibiting FLSs and monocyte function. Monocytes and FLS from RA patients were selected respectively, and cells from each patient were divided into two groups. One group was left untreated, and one group was treated with 5  $\mu\text{g}/\text{ml}$  CFH for 6 h. A Volcano plot indicated up-regulated (red dots) and down-regulated (blue dots) genes ( $P$  value  $< 0.05$  and  $|\log_2\text{FC}| > 0.5$ ) by RNA sequencing in CFH-treated versus untreated RA monocytes. EIF3C is indicated. B Volcano plot indicated up-regulated (red dots) and down-regulated (blue dots) genes ( $P$  value  $< 0.05$  and  $|\log_2\text{FC}| > 0.5$ ) by RNA sequencing in CFH-treated versus untreated RA monocytes. EIF3C and EIF3CL are indicated. C We selected the genes upregulated in the CFH-treated monocytes and the genes upregulated in the CFH-treated FLS identified by RNA-sequencing and determined the intersecting proteins. We obtained one gene, namely EIF3C. DEGs: Differentially Expressed Genes. D The boxplot shows the relative expression of EIF3C and EIF3CL. E CFH upregulated the protein expression of EIF3C by using Western blot. F CFH combined with TNF- $\alpha$  upregulated protein expression of EIF3C in both RA FLSs and monocytes by using Western blot. Data are expressed as mean  $\pm$  SEM ( $n = 6$ ). \* $p < 0.05$  Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/37996918>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



## Publications

Jia, Y;Feng, B;Ji, X;Tian, X;Zhao, L;Zhou, J;Zhang, W;Li, M;Fei, Y;Wu, X; Complement factor H attenuates TNF- $\alpha$ -induced inflammation by upregulating EIF3C in rheumatoid arthritis *Journal of translational medicine* 2023-11-23 [PMID: 37996918]

Santanusagna S, Zhu S, Jawalagatti V et al. Master transcription factor reprogramming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer *Cancer discovery* 2023-09-07 [PMID: 37676710] (WB)

Fujii K, Zhulyn O, Byeon GW Et al. Controlling tissue patterning by translational regulation of signaling transcripts through the core translation factor eIF3c *Developmental cell* 2021-11-08 [PMID: 34752747]

Jin HY, Oda H, Chen P et al. Differential Sensitivity of Target Genes to Translational Repression by miR-17-92. *PLoS Genet.* [PMID: 28241004] (WB, Mouse)

Chazal PE, Daguene E, Wendling C et al. EJC core component MLN51 interacts with eIF3 and activates translation *Proc Natl Acad Sci U S A* 2013-03-25 [PMID: 23530232] (WB, Human)



### **Novus Biologicals USA**

10730 E. Briarwood Avenue  
Centennial, CO 80112  
USA  
Phone: 303.730.1950  
Toll Free: 1.888.506.6887  
Fax: 303.730.1966  
nb-customerservice@bio-techne.com

### **Bio-Techne Canada**

21 Canmotor Ave  
Toronto, ON M8Z 4E6  
Canada  
Phone: 905.827.6400  
Toll Free: 855.668.8722  
Fax: 905.827.6402  
canada.inquires@bio-techne.com

### **Bio-Techne Ltd**

19 Barton Lane  
Abingdon Science Park  
Abingdon, OX14 3NB, United Kingdom  
Phone: (44) (0) 1235 529449  
Free Phone: 0800 37 34 15  
Fax: (44) (0) 1235 533420  
info.EMEA@bio-techne.com

### **General Contact Information**

www.novusbio.com  
Technical Support: nb-technical@bio-techne.com  
Orders: nb-customerservice@bio-techne.com  
General: novus@novusbio.com

### **Products Related to NB100-511**

---

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

---

### **Limitations**

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit [www.novusbio.com/guarantee](http://www.novusbio.com/guarantee)

Earn gift cards/discounts by submitting a review: [www.novusbio.com/reviews/submit/NB100-511](http://www.novusbio.com/reviews/submit/NB100-511)

Earn gift cards/discounts by submitting a publication using this product:  
[www.novusbio.com/publications](http://www.novusbio.com/publications)

